Grifols, SA (GB:0RDU)
LSE:0RDU
0RDU Stock Chart & Stats
€9.00
-€0.09(-0.95%)
At close: 4:00 PM EST
€9.00
-€0.09(-0.95%)
Day’s Range― - ―
52-Week Range€7.68 - €13.70
Previous CloseN/A
Volume20.05K
Average Volume (3M)125.85K
Market Cap
€5.57B
Enterprise Value€14.90B
Total Cash (Recent Filing)€825.49M
Total Debt (Recent Filing)€9.64B
Price to Earnings (P/E)18.7
Beta1.06
Next Earnings
Apr 30, 2026EPS Estimate
0.14Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.14
Shares Outstanding426,129,800
10 Day Avg. Volume28,144
30 Day Avg. Volume125,850
Financial Highlights & Ratios
PEG Ratio0.12
Price to Book (P/B)1.40
Price to Sales (P/S)0.98
P/FCF Ratio9.41
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€11.00Price Target Upside22.22% Upside
Rating ConsensusHold
Number of Analyst Covering1
EPS Forecast (FY)0.87
Revenue Forecast (FY)€7.78B
Bulls Say, Bears Say
Bulls Say
Vertically Integrated Plasma ModelOwning end-to-end plasma activities creates durable control of supply, margins and product quality. Vertical integration reduces reliance on third-party suppliers, supports scale in fractionation, and preserves capture of value across the product lifecycle, supporting steady long-term revenue and margin resilience.
Recurring-revenue Diagnostic BusinessInstalled instrument bases plus consumable demand generate predictable, annuity-like revenue streams. This recurring consumables model cushions cyclicality in therapeutics, improves revenue visibility, and supports aftermarket margins and cross-selling opportunities across hospitals and blood banks over multi-year horizons.
Improved Cash Generation And Positive FCFMaterial positive free cash flow and rising operating cash flow provide internal resources for reinvestment and gradual deleveraging. Sustained FCF supports capital spending for capacity, funds potential buybacks/dividends, and reduces refinancing stress, improving long-term financial flexibility if trends persist.
Bears Say
High Leverage And Weak Debt CoverageElevated absolute debt and high leverage constrain strategic flexibility and increase refinancing, interest and covenant risks. With operating cash flow small relative to total debt, deleveraging may be slow, leaving the company vulnerable to rate shocks or weaker free cash flow periods over the medium term.
Regulatory/operational Risk In Plasma CollectionRegulator-imposed conditions across collection centers pose sustained operational disruptions and raise compliance costs. Restrictions can reduce plasma intake capacity, increase remediation spending and damage reputation, creating multi-month to multi-year headwinds for raw material supply and revenue in core plasma therapeutics.
Margins Recovered But Below Historical Peak; Earnings VolatilityWhile margins rebounded, structural margin pressure remains versus prior peaks, indicating limited pricing or mix power and potential cost or capacity constraints. Historical profit volatility reduces forecasting reliability and suggests earnings could be sensitive to plasma supply, pricing, and integration or regulatory setbacks.
Grifols News
0RDU FAQ
What was Grifols, SA’s price range in the past 12 months?
Grifols, SA lowest share price was €7.68 and its highest was €13.70 in the past 12 months.
What is Grifols, SA’s market cap?
Grifols, SA’s market cap is €5.57B.
When is Grifols, SA’s upcoming earnings report date?
Grifols, SA’s upcoming earnings report date is Apr 30, 2026 which is in 19 days.
How were Grifols, SA’s earnings last quarter?
Grifols, SA released its earnings results on Feb 26, 2026. The company reported €0.144 earnings per share for the quarter, missing the consensus estimate of €0.255 by -€0.111.
Is Grifols, SA overvalued?
According to Wall Street analysts Grifols, SA’s price is currently Undervalued.
Does Grifols, SA pay dividends?
Grifols, SA does not currently pay dividends.
What is Grifols, SA’s EPS estimate?
Grifols, SA’s EPS estimate is 0.14.
How many shares outstanding does Grifols, SA have?
Grifols, SA has 426,129,800 shares outstanding.
What happened to Grifols, SA’s price movement after its last earnings report?
Grifols, SA reported an EPS of €0.144 in its last earnings report, missing expectations of €0.255. Following the earnings report the stock price went up 0.182%.
Which hedge fund is a major shareholder of Grifols, SA?
Currently, no hedge funds are holding shares in GB:0RDU
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Grifols Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
21.39%
12-Months-Change
Fundamentals
Return on Equity
7.56%
Trailing 12-Months
Asset Growth
-7.75%
Trailing 12-Months
Company Description
Grifols, SA
Grifols, S.A. engages in the procurement, manufacture, preparation, and sale of therapeutic products, primarily hemoderivatives. The company operates through Bioscience, Hospital, Diagnostic, Bio Supplies, and Others divisions. The Bioscience division researches, develops, produces, and markets plasma-derived medicines and other innovative solutions to treat patients with chronic, rare, prevalent, and life-threatening diseases. It offers immunoglobulins, alpha-1 antitrypsin, albumin, clotting factors, and hyperimmune globulins. The Hospital division offers non-biological pharmaceutical products and medical supplies clinical nutrition, intravenous therapy, and medical devices. The Diagnostic division researches, develops, produces, and commercializes diagnostic products that span the healthcare continuum from prevention, screening, diagnosis, and prognosis to disease and treatment monitoring to serve professionals. The Bio Supplies division provides biological materials for life-science research, clinical trials, and for manufacturing pharmaceutical and diagnostic products. Its products and services are used by healthcare providers to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases, and other medical conditions. The company serves public and private customers; and wholesalers, distributors, group purchasing organizations, blood banks, hospitals and care institutions, and national health systems. Grifols, S.A. has a technology collaboration agreement with Mondragon. The company was founded in 1940 and is headquartered in Barcelona, Spain.
0RDU Stock 12 Month Forecast
Average Price Target
€11.00
▲(22.22% Upside)
Technical Analysis
Almirall
―
Faes Farma
―
LABORATORIO REIG JOFRE
―
Laboratorios Farmaceuticos Rovi
―
Pharma Mar SA
―
Options Prices
Currently, No data available
---